{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"LNAI","limit":50},"count":50,"signals":[{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":21,"context":"sons shall have the meaning ascribed to such term in Section 3.1(qq). Liens means a lien, charge pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Money Laundering Laws shall have the meaning ascribed","filed_date":"2025-11-25","accession":"0001731122-25-001597","full_text":"https://origin.rootz.global/static/filing/0001731122-25-001597.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":23,"context":"stockholders or until their successors are duly elected and qualified (Election of Directors); | | |  |  |  | | |  |  2. |  To approve by a non-binding advisory vote the compensation of the Companys named executive officers, as disclosed in this proxy statement (the Say-on-Pay Proposal); | | |  |  |  | | |  |  3. |  To approve by a non-binding advisory vote the appointment of Sadler, Gibb & Associates LLC (Sadler) as t","filed_date":"2025-10-15","accession":"0001731122-25-001378","full_text":"https://origin.rootz.global/static/filing/0001731122-25-001378.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":57,"context":"on of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on our business, financial condition, results of operations and cash flows. **Other Healthcare Laws and Compliance Regulations** Although we currently do not have any products on the market, we may a","filed_date":"2025-09-29","accession":"0001731122-25-001316","full_text":"https://origin.rootz.global/static/filing/0001731122-25-001316.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":57,"context":"on of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on our business, financial condition, results of operations and cash flows. 17 **Other Healthcare Laws and Compliance Regulations** Although we currently do not have any products on the market, we ma","filed_date":"2025-02-19","accession":"0001731122-25-000252","full_text":"https://origin.rootz.global/static/filing/0001731122-25-000252.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":57,"context":"on of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on our business, financial condition, results of operations and cash flows. 17 **Other Healthcare Laws and Compliance Regulations** Although we currently do not have any products on the market, we ma","filed_date":"2024-10-10","accession":"0001731122-24-001578","full_text":"https://origin.rootz.global/static/filing/0001731122-24-001578.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"ers. If we do not obtain required additional equity or debt funding, our cash resources will be depleted and we could be required to materially reduce or suspend operations, which would likely have a material adverse effect on our business, stock price and our relationships with third parties with whom we have business relationships, at least until additional funding is obtained. If we do not have sufficient funds to co","filed_date":"2024-05-15","accession":"0001731122-24-000807","full_text":"https://origin.rootz.global/static/filing/0001731122-24-000807.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":21,"context":"on of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on our business, financial condition, results of operations and cash flows. The FDA offers several programs to expedite the development of products that treat serious or life-threatening illnesses an","filed_date":"2023-10-02","accession":"0001731122-23-001770","full_text":"https://origin.rootz.global/static/filing/0001731122-23-001770.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":16,"context":"ll proportionate adjustment thereto made pursuant to Section 2(a) hereof for or in respect of such reorganization, recapitalization, non-cash dividend, stock split, or other similar transaction. (o)  Material Adverse Effect means any material adverse effect on (i) the enforceability of any Transaction Document, (ii) the results of operations, assets, business or financial condition of the Company and its Subsidiaries, t","filed_date":"2023-06-27","accession":"0001731122-23-001210","full_text":"https://origin.rootz.global/static/filing/0001731122-23-001210.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":41,"context":"Directors. Each of the seven (7) nominees will be elected by a plurality of votes cast at the 2023 Meeting, which means that the seven (7) nominees who receive the highest number of FOR votes will be elected as directors. Abstentions and broker non-votes will have no effect on the outcome of Proposal 1. | | |  |  |  | | |  |  |  Proposal 2. Approval of Incentive Plan. The 2023 Equity Incentive Plan will be approved","filed_date":"2023-05-16","accession":"0001731122-23-000962","full_text":"https://origin.rootz.global/static/filing/0001731122-23-000962.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":21,"context":"on of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on our business, financial condition, results of operations and cash flows. The FDA offers several programs to expedite the development of products that treat serious or life-threatening illnesses an","filed_date":"2023-02-27","accession":"0001731122-23-000271","full_text":"https://origin.rootz.global/static/filing/0001731122-23-000271.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":19,"context":"on of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on our business, financial condition, results of operations and cash flows *Orphan Drug Designation* Under the Orphan Drug Act, the FDA may grant orphan designation to a product intended to treat a r","filed_date":"2021-09-24","accession":"0001731122-21-001565","full_text":"https://origin.rootz.global/static/filing/0001731122-21-001565.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":29,"context":"ly elected and qualified. | | |  |  |  | | |  |  |  Proposal 2. Non-Binding, Advisory Approval of Executive Compensation. The approval, on a non-binding advisory basis of the compensation paid to our named executive officers. | | |  |  |  | | |  |  |  Proposal 3. Non-Binding, Advisory Vote on Frequency of Future Advisory Votes on the Compensation Paid to our Named Executive Officers. The approval, on a non-binding advis","filed_date":"2021-02-03","accession":"0001731122-21-000160","full_text":"https://origin.rootz.global/static/filing/0001731122-21-000160.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"by Congress, or fiscal challenges faced by all levels of government health administration authorities, or by similar changes in foreign countries. The implementation of any such changes could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects, including our share price and ability to raise capital. **Risks Related to Our Intellectual Property","filed_date":"2020-09-23","accession":"0001731122-20-000975","full_text":"https://origin.rootz.global/static/filing/0001731122-20-000975.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"be prepared and filed by the Company with the SEC pursuant to Rule 424(b) under the Securities Act and in accordance with Section 5(b), including the documents incorporated by reference therein. (o)  Material Adverse Effect means any material adverse effect on (i) the enforceability of any Transaction Document, (ii) the results of operations, assets, business or financial condition of the Company and its Subsidiaries, t","filed_date":"2020-07-14","accession":"0001731122-20-000727","full_text":"https://origin.rootz.global/static/filing/0001731122-20-000727.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"in FDA policy during the period of product development, clinical trials and FDA regulatory review. Any delay or failure in our clinical trial program and in obtaining required approvals would have a material adverse effect on our ability to generate revenues from the particular product. Furthermore, any regulatory approval to market a product may be subject to limitations on the indicated uses for which we may market t","filed_date":"2016-09-28","accession":"0001213900-16-017105","full_text":"https://origin.rootz.global/static/filing/0001213900-16-017105.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"in FDA policy during the period of product development, clinical trials and FDA regulatory review. Any delay or failure in our clinical trial program and in obtaining required approvals would have a material adverse effect on our ability to generate revenues from the particular product. Furthermore, any regulatory approval to market a product may be subject to limitations on the indicated uses for which we may market t","filed_date":"2015-03-31","accession":"0001213900-15-002253","full_text":"https://origin.rootz.global/static/filing/0001213900-15-002253.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":27,"context":"with an explanatory paragraph to the effect that there is substantial doubt about DanDrits ability to continue as a going concern. This unqualified opinion with an explanatory paragraph could have a material adverse effect on DanDrits business, financial condition, results of operations and cash flows. DanDrit had net losses at March 31, 2014 and 2013 of $426,054 and $399,072, respectively and December 31, 2013 and 201","filed_date":"2014-08-08","accession":"0001213900-14-005536","full_text":"https://origin.rootz.global/static/filing/0001213900-14-005536.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"inion with an explanatory paragraph to the effect that there is substantial doubt about its ability to continue as a going concern. This unqualified opinion with an explanatory paragraph could have a material adverse effect on DanDrits business, financial condition, results of operations and cash flows. DanDrit had net losses at December 31, 2012 and 2011 of $2,427,649 and $1,664,180, respectively. DanDrit expects to co","filed_date":"2014-02-14","accession":"0001213900-14-000933","full_text":"https://origin.rootz.global/static/filing/0001213900-14-000933.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":9,"context":"Tech A/S (275,871 common shares post reverse acquisition). [C]To record the issuance of 1,400,000 and 40,000 common shares of Putnam Hills Corp for consultingand legal services in connection with the acquisition and offering valued at $5 per share or $7,000,000 and $200,000, respectfully. [D]To record the February 12, 2014 acquisition of a 97% interest in the SUBSIDIARY by the PARENT through the issuance of 5,814,945 shares of commo","filed_date":"2014-02-14","accession":"0001213900-14-000933","full_text":"https://origin.rootz.global/static/filing/0001213900-14-000933.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":54,"context":"on of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on our business, financial condition, results of operations and cash flows. **Other Healthcare Laws and Compliance Regulations** Although we currently do not have any products on the market, we may a","filed_date":"2026-10-13","accession":"0001731122-26-001339","full_text":"https://origin.rootz.global/static/filing/0001731122-26-001339.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":14,"context":"14,648 | | | F-16 On February 13, 2024, the Company acquired Renovaro Cube as a wholly owned subsidiary pursuant to a stock purchase agreement.As part of the acquisition of Renovaro Cube, the Company acquired goodwill valued at $159,464,039. On April 8, 2025, the Company acquired BioSymetrics, Inc. as a wholly owned subsidiary pursuant to a stock purchase agreement.As part of the acquisition of BioSymetrics, Inc., the Company","filed_date":"2026-10-13","accession":"0001731122-26-001339","full_text":"https://origin.rootz.global/static/filing/0001731122-26-001339.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":92,"match_count":9,"context":"VENT** In accordance with ASC 855-10, Company management reviewed all material events through the date of this report. The following material subsequent events occurred. On July 11, 2017, the Company appointed Robert Wolfe as Chief Financial Officer. On July 12, 2017, the Company completed a private placement offering of 1,231,561 Units consisting of 1,231,561 shares of Common Stock and warrants to purchase 2,463,122 shares of","filed_date":"2017-09-29","accession":"0001213900-17-010130","full_text":"https://origin.rootz.global/static/filing/0001213900-17-010130.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"ed Product Liability Directive seeking to establish a harmonized civil liability regime for AI in the European Union in order to facilitate civil claims in respect of harm caused by AI and to include AI-enabled products within the scope of the European Unions existing product liability regime. If enacted, this regulatory framework is expected to have a material impact on the way AI is regulated in the European Unio","filed_date":"2025-09-29","accession":"0001731122-25-001316","full_text":"https://origin.rootz.global/static/filing/0001731122-25-001316.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":86,"match_count":7,"context":"ough the Termination Date. In addition, Mr. Wolfe continues to serve as a director of the Company. In connection with Mr. Wolfes departure as Chief Financial Officer of DanDrit Denmark, Lone Degn was appointed to serve as Chief Financial Officer of DanDrit Denmark effective as of March 12, 2015. Subject to approval by the Companys Board of Directors and Mr. Wolfes resignation as Chief Financial Officer of the Company, it is","filed_date":"2015-03-31","accession":"0001213900-15-002253","full_text":"https://origin.rootz.global/static/filing/0001213900-15-002253.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":85,"match_count":5,"context":"year ended June 30, 2016 | | |  |  (3) |  Represents the six months ended June 30, 2015 | | |  |  (3) |  Represents the year ended December 31, 2014 | | **Employment Arrangements** **Agreements with Named Executive Officers** We have employments agreement with Dr. Leire, Ms. Degn and Mr. Robert Wolfe. ** ** | | 60 | | | ** ** **Leire Employment Agreement** Effective March 1, 2012, DanDrit Denmark entered into an Employ","filed_date":"2016-09-28","accession":"0001213900-16-017105","full_text":"https://origin.rootz.global/static/filing/0001213900-16-017105.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":80,"match_count":10,"context":"perty owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise)","filed_date":"2024-06-21","accession":"0001731122-24-001001","full_text":"https://origin.rootz.global/static/filing/0001731122-24-001001.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":80,"match_count":10,"context":"evs experience as an entrepreneur in successfully building start-up companies from the ground up qualifies him to serve as a director and Chairman of the Board. Dr. Mark Dybul. Dr. Dybul, age 58, was appointed our Chief Executive Officer (CEO) and principal executive officer, effective July 1, 2021. Previous to the appointment, he served as Executive Vice Chair of the Board since January of 2019 and as a director since February of 20","filed_date":"2022-01-27","accession":"0001731122-22-000109","full_text":"https://origin.rootz.global/static/filing/0001731122-22-000109.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":79,"match_count":8,"context":"ompensation for the years ended December 31, 2013 and 2012 earned by or paid to our chief executive officer and our one other executive officer in 2013 whose total compensation exceeded $100,000 (the named executive officers). Summary Compensation Table |  Name and Principal Position |  |  Year |  |  Salary ($) |  |  Bonus ($) |  |  Stock Awards ($) |  |  Option Awards ($) |  |  Nonequity Incentive Plan Compensation |","filed_date":"2014-08-08","accession":"0001213900-14-005536","full_text":"https://origin.rootz.global/static/filing/0001213900-14-005536.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":72,"match_count":9,"context":"n entrepreneur in successfully building start-up companies from the ground up qualifies him to serve as a director and Chairman of the Board. | 47 | | | | | **Dr. Mark Dybul**. Dr. Dybul, age 59, was appointed our Chief Executive Officer (CEO) and principal executive officer, effective July 1, 2021. Prior to the appointment, he served as Executive Vice Chair of the Board since January of 2019 and as a director since February of 2018.","filed_date":"2023-02-27","accession":"0001731122-23-000271","full_text":"https://origin.rootz.global/static/filing/0001731122-23-000271.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":67,"match_count":4,"context":"in FDA policy during the period of product development, clinical trials and FDA regulatory review. Any delay or failure in our clinical trial program and in obtaining required approvals would have a material adverse effect on our ability to generate revenues from the particular product. Furthermore, any regulatory approval to market a product may be subject to limitations on the indicated uses for which we may market t","filed_date":"2017-09-29","accession":"0001213900-17-010130","full_text":"https://origin.rootz.global/static/filing/0001213900-17-010130.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"ed Product Liability Directive seeking to establish a harmonized civil liability regime for AI in the European Union in order to facilitate civil claims in respect of harm caused by AI and to include AI-enabled products within the scope of the European Unions existing product liability regime. If enacted, this regulatory framework is expected to have a material impact on the way AI is regulated in the European Unio","filed_date":"2025-02-19","accession":"0001731122-25-000252","full_text":"https://origin.rootz.global/static/filing/0001731122-25-000252.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"ed Product Liability Directive seeking to establish a harmonized civil liability regime for AI in the European Union in order to facilitate civil claims in respect of harm caused by AI and to include AI-enabled products within the scope of the European Unions existing product liability regime. If enacted, this regulatory framework is expected to have a material impact on the way AI is regulated in the European Unio","filed_date":"2024-10-10","accession":"0001731122-24-001578","full_text":"https://origin.rootz.global/static/filing/0001731122-24-001578.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The Affordable Care Act contains a number of provisions, including those governing enrollments in federal healthcare programs, reimbursement adjustments and fraud and abuse changes. Additionally, the Affordable Care Act increases the minimum level of Medicaid rebates payable by manufacture","filed_date":"2021-09-24","accession":"0001731122-21-001565","full_text":"https://origin.rootz.global/static/filing/0001731122-21-001565.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"a wholly owned subsidiary pursuant to a stock purchase agreement. In August 2023, the Company changed its corporate name from Enochian Biosciences Inc. to Renovaro Biosciences Inc. The Company is an AI-driven platform for precision medicine, diagnostics, and biodefense. Its proprietary technologies transform complex biomedical data into predictive insights, enabling faster discovery, greater accuracy, and strategi","filed_date":"2026-10-13","accession":"0001731122-26-001339","full_text":"https://origin.rootz.global/static/filing/0001731122-26-001339.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The Affordable Care Act contains a number of provisions, including those governing enrollments in federal healthcare programs, reimbursement adjustments and fraud and abuse changes. Additionally, the Affordable Care Act increases the minimum level of Medicaid rebates payable by manufacture","filed_date":"2023-02-27","accession":"0001731122-23-000271","full_text":"https://origin.rootz.global/static/filing/0001731122-23-000271.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":56,"match_count":7,"context":"*While our Board does not have a specific policy on whether the offices of Chairman of the Board and our principal executive officer should be separate or whether the Chairman of the Board should be selected from among the independent directors, but during our past three fiscal years the positions of principal executive officer and Chairman of the Board have been held by different individuals. Currently, pursuant to our Bylaws, which provi","filed_date":"2020-05-22","accession":"0001731122-20-000559","full_text":"https://origin.rootz.global/static/filing/0001731122-20-000559.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":53,"match_count":6,"context":"l Reporting** During the year ended June 30, 2018, we instituted the changes in our management and board related to our internal control over financial reporting: |  |  |  on July 11, 2017, the Board appointed Robert Wolfe as the Chief Financial Officer; | | |  |  |  on February 28, 2018, the Board increased its size from two to four directors and appointed two additional directors, one of whom who is considered independent under t","filed_date":"2018-10-01","accession":"0001731122-18-000094","full_text":"https://origin.rootz.global/static/filing/0001731122-18-000094.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The Affordable Care Act contains a number of provisions, including those governing enrollments in federal healthcare programs, reimbursement adjustments and fraud and abuse changes. Additionally, the Affordable Care Act increases the minimum level of Medicaid rebates payable by manufacture","filed_date":"2023-10-02","accession":"0001731122-23-001770","full_text":"https://origin.rootz.global/static/filing/0001731122-23-001770.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"osen the ties that bind, while preserving the fundamentals of basic scientific progress. Enochian BioSciences underlying scientific ideas are innovative with an elegant simplicity that is often the hallmark of groundbreaking advances. And we are working to push through systems and barriers to translate those disruptive ideas into potential products that could save many lives. Remarkable Progress ** *","filed_date":"2022-01-24","accession":"0001731122-22-000092","full_text":"https://origin.rootz.global/static/filing/0001731122-22-000092.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":48,"match_count":6,"context":"r organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted except as would not be expected to result in: (i) a Material Adverse Effect on the legality, validity or enforceability of this Agreement, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Co","filed_date":"2020-03-31","accession":"0001731122-20-000335","full_text":"https://origin.rootz.global/static/filing/0001731122-20-000335.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":48,"match_count":6,"context":"perty owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise)","filed_date":"2019-11-26","accession":"0001731122-19-000739","full_text":"https://origin.rootz.global/static/filing/0001731122-19-000739.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"ting charges, and late charges that may be imposed upon Landlord by the terms of any encumbrance or note secured by an encumbrance covering the Building or any portion thereof. Therefore, if any installment of rent or any other amount due from Tenant under this lease is not received by Landlord within five (5) business days after the date when due, Tenant shall pay to Landlord, upon demand, an additi","filed_date":"2018-06-25","accession":"0001731122-18-000021","full_text":"https://origin.rootz.global/static/filing/0001731122-18-000021.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":48,"match_count":6,"context":"of Surgical Gastroenterology at Copenhagen University and Dr. Mogen Claesson, a director of DanDrit designed the trial and proposed it to Dr. Fischer to act as sponsor and principal investigator. Enrollment of CRC patients started in October 2004 and the study ended in September 2006. Certain DanDrit staff, including Dr. Rosenberg and Dr. Claesson, as well as two other employees of DanDrit Denmark at","filed_date":"2015-03-31","accession":"0001213900-15-002253","full_text":"https://origin.rootz.global/static/filing/0001213900-15-002253.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":45,"match_count":5,"context":"s not have a formal policy on whether the offices of Chairman of the Board and Chief Executive Officer should be separate and, if they are to be separate, whether the Chairman of the Board should be selected from among the independent directors. The Board believes that it should have the flexibility to make these determinations at any given time in the way that it believes best to provide appropriate leadership for DanDrit at that time. Th","filed_date":"2016-11-21","accession":"0001213900-16-018778","full_text":"https://origin.rootz.global/static/filing/0001213900-16-018778.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":45,"match_count":5,"context":"s not have a formal policy on whether the offices of Chairman of the Board and Chief Executive Officer should be separate and, if they are to be separate, whether the Chairman of the Board should be selected from among the independent directors. The Board believes that it should have the flexibility to make these determinations at any given time in the way that it believes best to provide appropriate leadership for DanDrit at that time. Th","filed_date":"2015-12-01","accession":"0001213900-15-009195","full_text":"https://origin.rootz.global/static/filing/0001213900-15-009195.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":44,"match_count":3,"context":"nc. (DanDrit USA, the Company, we, us, or Parent) was originally incorporated in the State of Delaware on January 18, 2011 as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business. DanDrit BioTech A/S, a Danish corporation was incorporated on April 1, 2001 (DanDrit Denmark) and is a 100% owned subsidiary of the Company (subject to 123,464 common shares o","filed_date":"2018-02-09","accession":"0001213900-18-001473","full_text":"https://origin.rootz.global/static/filing/0001213900-18-001473.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":42,"match_count":4,"context":"SUBSEQUENT EVENTS** The Companys management reviewed material events through May 13, 2015. On April 28, 2015 Robert Wolfe resigned as Chief Financial Officer of the Company and on May 1st, the Board appointed Lone Degn as the Chief Financial Officer of the Company. On April 28, 2015 the Company entered into a service agreement with Fondazione Giscad per la Ricerca sui Tumori to support Dandrit in a clinical trial to be conducte","filed_date":"2015-05-13","accession":"0001213900-15-003597","full_text":"https://origin.rootz.global/static/filing/0001213900-15-003597.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":41,"match_count":2,"context":"e may be involved in litigation relating to claims arising out of our operations in the normal course of business. We are not currently a party to in any legal proceeding that we believe would have a material adverse effect on our business, financial condition or operating results. **Item 4. Mine Safety Disclosures.** ** ** Not applicable. | | 19 | | | **PART II** ** ** **Item 5. Market for Registrants Common Equity, Re","filed_date":"2018-10-01","accession":"0001731122-18-000094","full_text":"https://origin.rootz.global/static/filing/0001731122-18-000094.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":41,"match_count":2,"context":"we, us, or Parent) (formerly Putnam Hills Corp.) was originally incorporated in the State of Delaware on January 18, 2011 as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business. DanDrit BioTech A/S, a Danish corporation was incorporated on April 1, 2001 (DanDrit Denmark) and is a 96.92% owned subsidiary of the Company. The Company engages in the resea","filed_date":"2017-11-20","accession":"0001213900-17-012405","full_text":"https://origin.rootz.global/static/filing/0001213900-17-012405.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"LNAI","company":"Lunai Bioworks Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":40,"match_count":5,"context":"of Surgical Gastroenterology at Copenhagen University and Dr. Mogen Claesson, a director of DanDrit designed the trial and proposed it to Dr. Fischer to act as sponsor and principal investigator. Enrollment of CRC patients started in October 2004 and the study ended in September 2006. Certain DanDrit staff, including Dr. Rosenberg and Dr. Claesson, as well as two other employees of DanDrit Denmark at","filed_date":"2016-09-28","accession":"0001213900-16-017105","full_text":"https://origin.rootz.global/static/filing/0001213900-16-017105.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"500c6ba54a88c21f7ade485f734e06bcce49dff45654d6aa356eca0819da26de","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"ab6a019a0eea71ce0775efe58ddbbeb097e138ef8c2bfdf4f6fb0840c11821fc","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":99,"hourly_limit":500,"remaining":401,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}